Tafasitamab is available for use as a second line treatment in combination with lenalidomide
Incyte Biosciences is pleased to announce today that the HSE has recommended in favour of reimbursement of tafasitamab (Minjuvi®), under the Oncology Drug Management System (ODMS).
This means tafasitamab is available for use as a second line treatment in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
- DLBCL is the most common form of non-Hodgkin lymphoma,1 accounting for 25 to 30 per cent of all non-Hodgkin’s lymphoma diagnoses2 and typically takes an aggressive course.3
- In Ireland, the five-year survival of patients with newly diagnosed DLBCL is 62 per cent,4 and patients with refractory disease or who have experienced multiple relapses typically have a poor prognosis.5
- The median overall survival ranges from 4.4 to 10 months.6,7,8 Tafasitamab is a targeted immunotherapy, and this access announcement represents a major milestone for patients, their families and the clinical community – providing an innovative and efficacious treatment option for this cancer, to improve patient outcomes for those not eligible for ASCT.
Pete Williams, General Manager of Incyte Biosciences UK & Ireland said: “We are incredibly proud of this achievement and what it means for patients with R/R DLBCL. We are grateful to the Irish healthcare system for recognising the unmet need and prioritising access to Minjuvi® for this patient cohort.”
“Incyte Biosciences UK & Ireland is proud to support this patient group and deliver clinical advancements in areas of unmet need.”
References available upon request.